![]() |
TECHNOLOGY |
| Technology Medicinal Nanoengineering Platform Publications |
Accurins™BIND is discovering and developing AccurinsTM, proprietary new best-in-class therapeutics with superior target selectivity, and an improved therapeutic index. Leveraging our proprietary Medicinal Nanoengineering® platform, we develop Accurins that outperform conventional systemic drugs by selectively accumulating in diseased tissues and cells. The result is higher drug concentrations at the site of action with minimal off-target exposure, leading to markedly better efficacy and safety.
Accurin Components BIND's targeted Accurins consist of the following components that facilitate selective targeting of diseased cells and tissues:
|
| Copyright ©2011 | BIND Biosciences, Inc | home | contact us | privacy | site map | |
| BIND Biosciences, Inc. | 64 Sidney Street | Cambridge, MA 02139 | P: 617-491-3400 | ||